Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors

Tiina Kelkka, Angela Pizzolla, Juha Petteri Laurila, Tomas Friman, Renata Gustafsson, Eva Kallberg, Olof Olsson, Tomas Leanderson, Kristofer Rubin, Marko Salmi, Sirpa Jalkanen, Rikard Holmdahl

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

The NADPH oxidase 2 (NOX2) complex is a professional producer of reactive oxygen species (ROS) and is mainly expressed in phagocytes. While the activity of the NOX2 complex is essential for immunity against pathogens and protection against autoimmunity, its role in the development of malignant tumors remains unclear. We compared wild type and Ncf1m1J mutated mice, which lack functional NOX2 complex, in four different tumor models. Ncf1m1J mutated mice developed significantly smaller tumors in two melanoma models in which B16 melanoma cells expressing a hematopoietic growth factor FLT3L or luciferase reporter were used. Ncf1m1J mutated mice developed significantly fewer Lewis Lung Carcinoma (LLC) tumors, but the tumors that did develop, grew at a pace that was similar to the wild type mice. In the spontaneously arising prostate carcinoma model (TRAMP), tumor growth was not affected. The lack of ROS-mediated protection against tumor growth was associated with increased production of immunity-associated cytokines. A significant increase in Th2 associated cytokines was observed in the LLC model. Our present data show that ROS regulate rejection of the antigenic B16-luc and LLC tumors, whereas the data do not support a role for ROS in growth of intrinsically generated tumors. ? 2013 Kelkka et al.
Original languageEnglish
Article numbere84148
Number of pages10
JournalPLoS ONE
Volume8
Issue number12
DOIs
Publication statusPublished - 2013

Cite this